Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vor Biopharma Inc. (Vor Bio) SEC filings page on Stock Titan provides streamlined access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer trading under the symbol VOR, Vor Bio reports on its clinical-stage biotechnology business focused on telitacicept, a dual BAFF/APRIL fusion protein being developed for serious autoimmune diseases.
Through this page, readers can review current and historical filings such as Forms 10‑K and 10‑Q for detailed discussions of risk factors, financial condition, and the status of telitacicept clinical programs, along with Form 8‑K reports describing material events. Recent 8‑K filings have covered topics including underwritten public offerings of common stock, a private placement with institutional investors, a reverse stock split, changes to equity incentive plans, and governance updates involving Board and executive appointments.
Vor Bio also uses 8‑K filings to furnish investor presentations and clinical data updates, for example webcasts and slide decks discussing late-breaking Phase 3 results for telitacicept in Sjögren’s disease and IgA nephropathy, as well as global development plans in generalized myasthenia gravis. Other filings, such as proxy statements (DEF 14A), describe stockholder proposals related to equity plans, warrant issuances, and capital structure changes.
On Stock Titan, these documents are complemented by AI-powered summaries that highlight key points from lengthy filings, helping users quickly understand how new financings, clinical milestones, or corporate actions may affect Vor Bio’s capital structure and development strategy. Investors can also locate information related to registered offerings on Form S‑3, at‑the‑market sales programs, and other registration statements referenced in the company’s 8‑K disclosures. This page is designed to make it easier to follow the regulatory record behind VOR, from financial reporting to telitacicept’s progress through late-stage development.
Jean-Paul Kress, CEO, Chairman and Director of Vor Biopharma, was granted a significant stock option award on June 26, 2025. The derivative securities transaction involved 83,296,638 stock options with the following key terms:
- Exercise price set at $0.89 per share
- Options expire on June 25, 2035
- Vesting schedule: 25% vests on June 26, 2026, with remaining 75% vesting in equal monthly installments over 3 years
- Vesting contingent on continued service with company
This substantial equity grant aligns the CEO's interests with shareholders and suggests long-term commitment to the company. The low exercise price relative to typical biotech stock prices may indicate recent market challenges or strategic compensation planning.
Jean-Paul Kress has filed a Form 3 (Initial Statement of Beneficial Ownership) with the SEC upon joining Vor Biopharma (NYSE: VOR) as CEO and Chairman of the Board, effective June 25, 2025.
Key details from the filing:
- Kress currently holds no beneficial ownership of any Vor Biopharma securities, either direct or indirect
- He serves in dual roles as both Director and Executive Officer
- The filing was submitted by attorney-in-fact Sherell Bacchas on June 27, 2025
- Business address is listed as 100 Cambridgepark Drive, Suite 101, Cambridge, MA
This Form 3 filing is a standard regulatory requirement for new officers and directors of public companies, establishing their initial securities ownership baseline for future transaction reporting.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
